Exelixis (EXEL)
(Delayed Data from NSDQ)
$38.67 USD
-0.27 (-0.69%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $38.66 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Exelixis, Inc. has a PEG ratio of 0.76 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.58.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXEL 38.67 -0.27(-0.69%)
Will EXEL be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for EXEL
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Here's Why Exelixis (EXEL) is a Strong Value Stock
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Other News for EXEL
Is EXEL preparing to trend higher? 20 Day Moving Average Support shows up after dropping 0.69%
Notable Two Hundred Day Moving Average Cross - EXEL
Is EXEL positioned for a breakdown? Stochastic Sell Signal shows up after declining 1.24%
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)
Is EXEL gathering momentum? NR7 shows up after declining 1.61%